Skip to main content
Premium Trial:

Request an Annual Quote

ABI Reports Q4 Revenue Rise; Slumping Sales Causes Income to Dip

NEW YORK, July 25 - Applied Biosystems today reported that fourth-quarter earnings slid as customers scaled back spending on its genome sequencers.
 
Revenue in the period ended June 30 rose three percent to $417 million from $405 million one year ago, ABI said.

The company explained that while sales of its genome sequencers rose four percent to $191.4 million, sales of less expensive disposable tools fell three percent to $152.9 million. Revenue from service contracts, royalties, and out-sourced research, meanwhile, rose 17 percent to $64.7 million.

R&D spending costs jumped 19 percent, the company said. As a result, the company's fourth-quarter net income fell to $38.2 million, or $.18 per share, from $47.6 million, or $.22 per share, in the year-ago period.
 
Looking forward, the Applera unit reaffirmed expectations that revenue will grow in the "high single digits to low teens" rate in 2003, and that earnings per share will be between $.85 and $.95 per share. Earnings in the fiscal first and second quarters will be flat compared with previous quarters because of increased research and development spending, ABI said.

Click here for more information.

The Scan

J&J Booster Support

A US Food and Drug Administration advisory panel has voted to support a booster dose of Johnson & Johnson's SARS-CoV-2 vaccine, according to the Los Angeles Times.

To Keep the Cases Moving

The president of the UK Royal College of Pathologists tells the Financial Times that more investment is needed to tackle a backlog of cases.

NAS Expels Archaeologist

Science reports Luis Jaime Castillo Butters' expulsion is the first of an international member from the US National Academy of Sciences.

PLOS Papers on Angelman Syndrome-Like Cases, Salmonella Paratyphi A, SARS-CoV-2 in Brazil

In PLOS this week: exome sequencing analysis of Angelman syndrome-like cases, genetic epidemiology of Salmonella Paratyphi A, and more.